Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
出版年份 2015 全文链接
标题
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
作者
关键词
Systemic Lupus Erythematosus, Physical Component Summary, Minimal Clinically Important Difference, Standardize Response Mean, Belimumab
出版物
ARTHRITIS RESEARCH & THERAPY
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-05-27
DOI
10.1186/s13075-015-0658-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions
- (2012) David Wofsy et al. ARTHRITIS AND RHEUMATISM
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment
- (2011) K.M.A.C. Luijten et al. AUTOIMMUNITY REVIEWS
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnair
- (2011) Jinoos Yazdany ARTHRITIS CARE & RESEARCH
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Minimal Clinically Important Difference
- (2010) Robert J. Gatchel et al. SPINE
- Toward the development of criteria for global flares in juvenile systemic lupus erythematosus
- (2010) Hermine I. Brunner et al. ARTHRITIS CARE & RESEARCH
- Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus
- (2010) Hermine I. Brunner et al. ARTHRITIS CARE & RESEARCH
- Novel evidence-based systemic lupus erythematosus responder index
- (2009) Richard A. Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- The Minimally Important Difference for Patient Reported Outcomes in Systemic Lupus Erythematosus Including the HAQ-DI, Pain, Fatigue, and SF-36
- (2009) K. J. COLANGELO et al. JOURNAL OF RHEUMATOLOGY
- Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases
- (2008) T Y-T Lu et al. ANNALS OF THE RHEUMATIC DISEASES
- Disability in valued life activities among individuals with systemic lupus erythematosus
- (2008) Patricia Katz et al. ARTHRITIS AND RHEUMATISM
- Quality of life over time in patients with systemic lupus erythematosus
- (2008) Bindee Kuriya et al. ARTHRITIS AND RHEUMATISM
- Effects of rituximab on resistant SLE disease including lung involvement
- (2008) JA Reynolds et al. LUPUS
- Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort
- (2007) Jinoos Yazdany et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started